Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash grows, but more slowly than its trailing trend

Q1 FY2026 net change in cash of $6.32M (cash outflow) rose 61.6% year over year, behind the +301.3% change in trailing-twelve-month net change in cash. Sequentially, it fell 13.6% from the prior quarter. Over 3 fiscal years it compounded at +8.1% a year.

Context

  • Net change in cash amounted to 37.1% of revenue in FY2025, down 277.4 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +61.6% toward the trailing-twelve-month pace of +301.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.32M-13.6% QoQ
Last fiscal yearDec 2025
$12.43M+249.8% YoY
LTMMar 2026
$10.02M+301.3% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+61.6%——
1 year+249.8%——
3-year CAGR+8.1%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
12.43M USD
Year-over-year change
+249.8%

Net Change in Cash vs competitors

How OBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +301.3% is the 4th highest of 11, against a peer median of -33.6%.
  • Net change in cash amounts to 30.6% of revenue for OBIO, versus a peer median of 199.3%.
OBIO Competitors
Net Change in Cash for OBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$136.08M USD+196.3%—243.6%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$100M USD-769.9%+42.0%169491.5%
TARAProtara Therapeutics, Inc.LTM Mar 2026$76.72M USD-295.6%+113.7%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$27.12M USD+568.0%+19.1%12051.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$25.29M USD+542.2%-17.4%36.5%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$19.32M USD-224.2%—115.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$17.36M USD-13.1%-72.2%155.0%
IVAInventiva S.A.FY2025€14.17M EUR-79.7%+326.2%316.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$11.75M USD+1066.8%+102.1%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$10.02M USD+301.3%+8.1%30.6%
PYXSPyxis Oncology, Inc.LTM Mar 2026$6.99M USD-54.0%-65.1%50.5%
Peer median (excluding OBIO) —-33.6%+30.5%199.3%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Depreciation & Amortization181K222K287K308K327K
Deferred Income Tax288K0000
Stock-Based Compensation302K3.41M7.63M10.62M11.98M
Change in Working Capital2.6M(451K)(3.31M)(765K)(10.37M)
Accounts Receivables47K25K(3K)22K(3K)
Inventory1K(208K)131K(28K)(137K)
Accounts Payables1.08M0145K2.97M0
Other Working Capital1.47M(268K)(3.58M)(3.73M)(10.23M)
Other Non-Cash Items217K1.14M(1.61M)308K1.81M
Operating Cash Flow(19.43M)(29.29M)(46.13M)(50.56M)(48.96M)
Capital Expenditures(274K)(591K)(78K)(289K)(489K)
Acquisitions (Net)(13.29M)00(602K)0
Purchases of Investments(213K)(63.53M)(142.03M)(72.65M)(76.31M)
Sales of Investments13.5M0152.8M86.63M49.86M
Other Investing Activities13.29M0000
Investing Cash Flow13.02M(64.12M)10.69M13.09M(26.94M)
Debt Repayment(4M)3.55M(10.85M)15M17.91M
Common Stock Issued7K109.83M254K15.04M71.97M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7K(10.13M)56.81M(864K)(1.55M)
Financing Cash Flow(3.99M)103.26M46.22M29.17M88.33M
Effect of Forex Changes00000
Net Change in Cash(10.41M)9.85M10.78M(8.3M)12.43M
Free Cash Flow(19.7M)(29.88M)(46.21M)(50.85M)(49.45M)

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.